Improving therapy for prostate cancer

Abstract

Patients with locally advanced prostate cancer have a greater chance of survival if they receive goserelin plus radiotherapy, rather than radiotherapy alone, according to the results of a study presented at the 32nd Annual Meeting of the American Society of Clinical Oncology (ASCO) [ Philadelphia, US; May 1996 ]. The study provides the first clinical evidence of a survival benefit with this combination treatment. Also at the conference, the latest data were presented from a study comparing bicalutamide with flutamide, and from a trial investigating the role of antineoplastic chemotherapy in hormone-refractory prostate cancer.